Home Top Movers Savara Inc. (SVRA) Stock Trending Down as Phase 3 of IMPALA 2...

Savara Inc. (SVRA) Stock Trending Down as Phase 3 of IMPALA 2 Trial Expected to Commence Soon

Savara Inc. (SVRA) stock prices were down by 3.95% as of the market closing on May 4th 2021, bringing the price per share down to USD$1.70 at the end of the trading day.

11th Hour Failure

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

SVRA announced near the end of 2020 that the Phase 3 trial of AeroVanc did not meet its primary endpoint of mean absolute change from baseline to FEV percent predicted analyzed sequentially at the ends of varying cycles. The trial consisted of patients with cystic fibrosis who also had an MRSA lung infection undergoing multiple dosing cycles, with one cycle consisting of 28 days of treatment followed by 28 days of observation.

Dissolution of AeroVanc

Despite being well-tolerated, AeroVanc did not show a statistically significant improvement in the sequence of analysis ends. Furthermore, the treatment failed to result in a decrease in the frequency of pulmonary exacerbations as compared to placebos. The development of AeroVanc has been discontinued based on the results of the trial, with the company hoping the data collected will benefit future research in the field.

Strong Liquidity Position

As the financial reports for the fourth quarter of the fiscal year 2020 are being tabulated, SVRA forecasts a solid liquidity position at the end of the year. The company anticipates USD$25 million in debt and USD$82 million in cash, cash equivalents, and short-term investments. To facilitate this strategy, SVRA has implemented a plan focusing on the reduction of overall operating expenses. Making the company’s cost structure leaner and more effective will also require a reduction in SVRA workforce.

Reallocation of Resources

2021 saw the company entering the new year with a shifting in their priorities, with a renewed focus on key value drivers such as Molgradex in aPAP as well as the successful execution of the IMPALA 2 trial. In the interest of SVRA’s pipeline simplification strategy and the reallocation of existing resources, the company has discontinued the Apulmiq clinical development program.

Phase 3 IMPALA 2 trial

The continued vice grip of the global Covid-19 pandemic has presented challenges in the conducting of SVRA’s clinical trials. Nevertheless, the company continues to facilitate the initiation of the Phase 3 IMPALA 2 trial across Europe, North America, and Asia. As the effects of the pandemic continue to develop, SVRA focuses on conducting its clinical trial safely and quickly. The resulting Covid-19 mitigation strategies have pushed the expected start date for the trial from the end of Q1 2021 to the start of Q2 2021.

Future Outlook for SVRA

Armed with the capital generated from the closing of their USD$130 million public offering, SVRA is poised to allocate its resources towards projects that have a probability of profitability. With the third phase of the IMPALA 2 trial looming just ahead, current and potential investors are hopeful that the company will leverage its strengths to usher in a period of significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Amarin Corporation plc (NASDAQ: AMRN) stock plunged in the premarket trading session; here’s why

In the premarket trading session, Amarin Corporation plc (AMRN) stock had plunged by -4.56% to $4.4. AMRN stock closed previous session at $4.61 gaining...

Why Second Sight Medical Products, Inc. (EYES) stock is Popping High today?

Second Sight Medical Products, Inc. (EYES) stock announced two-year results of its Orion Study after which the EYES stock price happened to be green...

Luokung Technology Corp. (LKCO) Stock Undergoes Volatility as Appeal Over CCMC Designation is Underway

Luokung Technology Corp. (LKCO) stock prices were down by 6.40% as of the market closing on May 11th, 2021, bringing the price per share...

Vista Gold Corp. (VGZ) Stock Inches Higher After Promising Q1 2021 Financial Reports

Vista Gold Corp. (VGZ) stock prices were up by an incremental 1.82% as of the market closing on May 11th, 2021, bringing the price...

Array Technologies, Inc. (ARRY) Stock Prices Stay Stable Despite Troubling Q1 2021 Financial Reports

Array Technologies, Inc. (ARRY) stock prices were up by a marginal 0.28% as of the market closing on May 11th, 2021, bringing the price...

Lucira Health Inc. (NASDAQ:LHDX) stock rallied today in the current trading session; here’s why

In the current trading session at last check, Lucira Health Inc. (LHDX) shares had surged by 15.32% to the price of $5.87. LHDX's stock...

PaySign, Inc. (PAYS) Stock Down Following Disclosure of Troubling Q1 2021 Financial Reports

PaySign, Inc. (PAYS) stock prices were down 15.0568% early in the trading day on May 12th, 2021, bringing the price per share down to...

Comstock Mining Inc. (NASDAQ:LODE) stock plunged in the current trading session; here’s why

In the current trading session at the last check, Comstock Mining Inc. (LODE) stock had plunged -3.25% to trade at $3.21. LODE stock previously...

Related News

Why Summit Wireless Technologies, Inc. (WISA) stock is Going high today?

Summit Wireless Technologies, Inc. (WISA) stock, a wireless sound technology company, provided an update for its first quarter ended March 31, 2021, today on...

Contextlogic Inc. (NASDAQ: WISH) stock rises during pre-market session. Let’s figure out why?

Contextlogic Inc. (NASDAQ: WISH) stock plunged by 0.84% at last close whereas the WISH stock price gains by 4.84% during pre-market session. WISH, which...

Biomerica Inc. (NASDAQ: BMRA) stock gains during pre-market. What’s driving it high?

Biomerica Inc. (NASDAQ: BMRA) stock declined by 17.23% at last close but later in pre-market session the BMRA stock soars by 13.78%. Biomerica is...

AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; here’s why

In the premarket trading session, at last check AGE stock surged by 7.2% to $1.34. AGE stock closed previous session at $1.25 losing -3.85%....

CuriosityStream Inc. (NASDAQ: CURI) stock fell during after-hour. Why is it so?

CuriosityStream Inc. (NASDAQ: CURI) stock declined by 3.37% at last close while the CURI stock continues to fall by 11.99% in the after-hour trading....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.